LipiGesic M Is The Only Recommended First-line Therapy For Acute Migraine That Has No Evidence Of Rebound Headache
SCHOFIELD, Wis., Aug. 5, 2013 /PRNewswire/ -- PuraMed BioScience ®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that its product, LipiGesic ® M, a homeopathic formulation of feverfew and ginger that eliminates migraine pain and associated symptoms, is the only recommended first-line therapy for acute migraine in the retail market today that has shown no evidence of rebound or medication-overuse headache.
Rebound, or medication-overuse headaches typically result when a person suffering migraines takes an OTC pain reliever or prescription migraine medication more than twice a week. According to the American Headache Society, all acute treatments can produce a medication-over-use or rebound headache.
However, LipiGesic M is Not Associated With Rebound Headache.
In the article, Advances in Drug Development for Acute Migraine, published in Drugs medical journal in December 2012, the authors, including headache expert Dr. Roger Cady, said of LipiGesic M, "Advantages of this product include lower cost, OTC availability, and it is not likely to produce medication-overuse headache. It is an excellent first-line therapy for very early intervention, as it is compatible with all other acute treatment options.""To my knowledge, there have been no reported incidences of LipiGesic M causing a rebound headache, no matter how frequently a person uses it to treat migraine pain," said Russ Mitchell, CEO of PuraMed BioScience. "Migraineurs who rely on the commonly used prescription migraine medications and over-the-counter migraine formulations run a high risk for rebound headache, but our product, LipiGesic M, has been shown to have none of those effects. "With the widespread incidence of rebound headache associated with migraine medications, and the increased number of Food and Drug Administration warnings associated with acetaminophen, it is personally fulfilling to offer a treatment for acute migraine that works as well as the top-selling triptan products, but without increasing health risks," said Mitchell. "Having watched a loved one suffer with migraine pain, I am thankful that I'm able to provide consumers with a product that stops migraines fast without the risk of further harm."
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV